Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881710 | 0.94 | HTT (0.64) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1609171 | 0.90 | HTT (0.58) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL14116535 | 0.89 | HTT (0.45) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL3928131 | 0.89 | MAPT (0.51) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL3928138 | 0.89 | MAPT (0.51) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL13876933 | 0.89 | KMT2A (0.51) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL3971120 | 0.88 | MAPT (0.48) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL584707 | 0.87 | HTT (0.55) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL18406296 | 0.83 | HTT (0.48) | HTTMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL26914012 | 0.83 | MAPT (0.60) | HTTMAPTALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| EP-1670769-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20060205802-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670770-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670769-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1636214-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | Astrazeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030733-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030732-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004108712-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | HTT 3623/4885MAPT 3892/4885ALDH1A1 165/4885 |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | H1-3, H1-4, CYP3A4 | HTT 4097/4885MAPT 3719/4885ALDH1A1 429/4885 |
| US-20060205802-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | H1-3, CYP2C19, CYP3A4 | HTT 4185/4885MAPT 3771/4885ALDH1A1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.